Coronavirus & Atopic Dermatitis Reporting Database

Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD, syn. atopic eczema), we have created a secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry.

We encourage clinicians worldwide to report ALL cases of COVID-19 in their AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).

Approximately 5 minutes

Reporting a case to this Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-AD registry should take approximately 5 minutes.

Please report all confirmed or clinically suspected COVID-19 cases, and report after sufficient time has passed to observe the disease course through resolution of acute illness and/or death.

With the collaboration of the international AD community, we will rapidly be able to define the impact of COVID-19 on patients with AD who are treated with systemic immunomodulating medication and how factors such as age, comorbidities, and AD systemic immunomodulating treatments impact COVID outcomes.

Key points:

• This is an international effort—we are counting on robust participation and collaboration
• We will provide the AD community with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. so the entire AD community has access to these data
• The registry collects only de-identified data, in accordance with Article 11 of the General Data Regulation (2016/679/EU) and is processed in accordance to Article 6 d and e and Article 9 paragraph 2 g, h, i and j; and in accordance with HIPAA Safe Harbor De-Identification Standards.
• We have taken steps to guarantee the safety and security of the registry in accordance with EU Data Protection Requirements

We hope you will actively contribute to this voluntary reporting system. Through broadscale participation and collaboration, we will be able to answer these very pressing questions for our AD patients and their caregivers.

We will provide regular, open access summaries of all reported cases in SECURE-AD, for the benefit of the international AD community.

AD Physician Registry
Login